Department of Internal Medicine, Ohio State University, Columbus, OH, USA.
Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Addiction. 2022 Nov;117(11):2933-2942. doi: 10.1111/add.15994. Epub 2022 Jul 14.
To measure the prevalence and changes in smokers' discussions with health professionals (HPs) about nicotine vaping products (NVPs) and HPs' recommendations about NVPs between 2016 and 2020, and their associations with tobacco product use transitions.
Cohort study using multinomial logistic regression analyses on data from waves 1 (2016), 2 (2018) and 3 (2020) from the International Tobacco Control Four Country Smoking and Vaping Surveys.
Four countries with varying NVP regulatory environments: 'most restrictive' (Australia), 'somewhat restrictive' (Canada) and 'less restrictive' (England and the United States).
Adult exclusive daily smokers who did not report NVP use at the time of their baseline survey and had visited a HP in the last 12-24 months. Prevalence data came from 4125, 4503 and 4277 respondents, respectively, for each year. Longitudinal data were from 4859 respondents who participated in at least two consecutive surveys.
Prevalence of self-reported discussions with HPs and recommendations from HPs about NVPs. Longitudinal transitions from smoking to vaping (either exclusively or concurrently with smoking) and quitting (regardless of NVP uptake).
The prevalence of NVP discussions was low among countries with varying regulatory environments and study waves (range = 1.4-6.2%). In 2020, a low percentage of smokers who discussed NVPs with a HP reported that their HPs recommended they use NVPs in the United States (14.7%), Australia (20.2%), Canada (25.7%), with a higher percentage in England (55.7%) where clinical guidelines for smoking cessation include NVPs. Compared with 12.0% of smokers who reported no discussion, 37.0% of those whose HPs recommended NVPs transitioned to vaping at follow-up. Transition to quitting was 9.6% with HPs' recommendation of NVPs versus 13.5% without discussion, a non-significant difference.
In Australia, Canada, England and the United States between 2016 and 2020, health professionals' discussions with smokers about nicotine vaping products (NVPs) were infrequent. NVP discussions were associated with NVP uptake, but not with quitting smoking.
测量 2016 年至 2020 年间吸烟者与健康专业人员（HP）讨论尼古丁电子烟产品（NVP）的频率变化，以及 HP 对 NVP 的推荐意见的变化，并探讨这些变化与烟草制品使用转变的关系。
利用来自国际烟草控制四国吸烟和电子烟调查 1 波（2016 年）、2 波（2018 年）和 3 波（2020 年）的数据，采用多项逻辑回归分析进行队列研究。
四个国家的 NVP 监管环境不同：“最严格”（澳大利亚）、“稍严格”（加拿大）和“较宽松”（英格兰和美国）。
在基线调查时没有报告使用 NVP 的成年纯吸烟人群，且在过去 12-24 个月内看过 HP。每个年份的流行数据分别来自 4125、4503 和 4277 名受访者。纵向数据来自至少连续参加两次调查的 4859 名受访者。
自我报告与 HP 讨论 NVP 以及 HP 对 NVP 推荐的频率。从吸烟到吸电子烟（单独使用或与吸烟同时使用）和戒烟（无论是否使用 NVP）的纵向转变。
在监管环境和研究波次不同的国家，NVP 讨论的比例较低（范围为 1.4%-6.2%）。在 2020 年，与 HP 讨论过 NVP 的吸烟者中，报告其 HP 建议他们使用 NVP 的比例较低，在美国（14.7%）、澳大利亚（20.2%）和加拿大（25.7%），而在英格兰（55.7%）这一比例较高，那里的戒烟临床指南包括 NVP。与没有讨论的吸烟者（12.0%）相比，37.0%的 HP 推荐使用 NVP 的吸烟者在随访中转为吸电子烟。在 HP 推荐使用 NVP 时，吸烟者戒烟的比例为 9.6%，而没有讨论时为 13.5%，差异无统计学意义。
在 2016 年至 2020 年期间，澳大利亚、加拿大、英格兰和美国的健康专业人员与吸烟者讨论尼古丁电子烟产品（NVP）的频率较低。NVP 讨论与 NVP 使用相关，但与戒烟无关。
